In the ATTRACTION-4 trial, nivolumab combined with oxaliplatin-based chemotherapy significantly improved PFS in Asian patients with HER2-negative, unresectable advanced or recurrent GC, though it did not improve OS. Here, ERBB2 is linked to gastric cancer.